拉夏貝爾A股漲停帶動H股漲超11% 成交較淡
格隆匯6月4日丨拉夏貝爾(603157.SH)於上午11點漲停,報3.74元,截至收盤有1.85萬手封單封住漲停板。港股拉夏貝爾(6116.HK)被帶動,從11點開始出現明顯上漲,截至目前漲11.11%報0.8港元,唯成交僅671.68萬港元。拉夏貝爾A股曾於今年5月19日創出歷史新低價2.82元,H股曾於5月18日創出歷史新低價0.65港元。公司6月1日公告,截至2020年5月31日,公司通過集中競價交易方式已累計回購A股股份357.32萬股,佔公司總股本的0.65%,佔A股股本的1.07%,成交價格區間為4.14元-6.15元/股,回購金額2000.995萬元(不含交易費用)。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.